Scientist/senior Principal Scientist

Eli Lilly Eli Lilly · Pharma · Indianapolis, IN

Scientist/Senior Principal Scientist role in Bioanalytical Research at Eli Lilly, focusing on quantitative bioanalysis, metabolite identification, and biotransformation characterization for small molecule therapeutics. Requires method development, structural elucidation using mass spectrometry, and cross-functional collaboration.

What you'd actually do

  1. Develop and validate quantitative LC-MS/MS bioanalytical methods for small molecule drug candidates in biological matrices (plasma, tissue, urine, bile).
  2. Perform metabolite identification (Met-ID) studies using high-resolution mass spectrometry (HRMS), integrating data from in vitro and in vivo systems to characterize biotransformation pathways.
  3. Serve as the bioanalytical lead on discovery programs, partnering closely with medicinal chemistry, DMPK, and toxicology teams to inform compound optimization and candidate selection.
  4. Apply MS-informatics tools for automated data processing, spectral interpretation, and metabolite structure elucidation.
  5. Interpret complex MS datasets and communicate clear, actionable scientific insights to project teams and leadership.

Skills

Required

  • BS with 7+ years in bioanalytical experience
  • quantitative LC-MS/MS method development for small molecules
  • sample preparation optimization
  • matrix effect evaluation
  • assay validation
  • high-resolution mass spectrometry (Orbitrap, QTOF) for metabolite identification and structural characterization
  • small molecule ADME principles
  • drug metabolism pathways

Nice to have

  • MS with 5+ years of relevant bioanalytical experience
  • MS-informatics tools such as Compound Discoverer, MassMetaSite, MetaSite, or Metabolynx
  • triple quadrupole (QQQ) LC-MS/MS platforms (e.g., Sciex, Waters, Agilent)
  • in vitro metabolism systems (microsomes, hepatocytes, S9 fractions)
  • reaction phenotyping approaches
  • supporting regulatory submissions (IND-enabling studies, DDI assessments)
  • reactive metabolite trapping experiments
  • bioactivation risk assessment
  • New Approach Methodologies (NAMs) studies
  • bioanalysis of samples from organ-on-chip, 3D cell culture, or microphysiological systems
  • quantitative mass spectrometry imaging platforms (MALDI-MSI, DESI, IR-MALDESI)
  • ICP-MS for elemental analysis
  • quantitation of metal-containing therapeutics
  • radioligand therapeutic (RLT) bioanalysis
  • multi-platform strategies integrating LC-MS, ICP-MS, and radio-HPLC

What the JD emphasized

  • Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.